Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Brief Summary: This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and efficacy study. The aim of this study is to evaluate the effect of an intravitreal fluocinolone acetonide (0.59 mg) implant compared to standardized therapy in subjects with unilateral or bilateral, non-infectious uveitis affecting the posterior segment of the eye.


Options:
A: Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician.

Exclusion: Females who are pregnant or lactating, and females of childbearing potential not using adequate birth control for the duration of the study. Any intraocular procedures or laser treatment less than 90 days before enrollment.
B: Inclusion Criteria:

* Males or non-pregnant females at least 6 years of age who had been diagnosed and treated for recurrent, non-infectious uveitis affecting the posterior segment of one or both eyes for at least 1 year prior to the start of the study, and had 'quiet' eyes at surgery

Exclusion Criteria:

* Coexisting medical or ocular conditions that would interfere with the study results
C: Inclusion Criteria:

* 18 years or older with a diagnosis of chronic intermediate uveitis in at least one eye

Exclusion Criteria:

* Uncontrolled systemic disease
* Any active ocular infections
D: Inclusion Criteria:

* Males and non-pregnant females at least 6 years of age
* History of recurrent unilateral or asymmetric non-infectious posterior uveitis of at east 1 year duration not associated with significant systemic activity of the disease
* The more severely affected eye having had at least 2 separate recurrences
* The more severely affected eye having been treated by systemic therapy for at least one month just before inclusion
* Visual acuity (VA) of at least 1.4 logMAR units at enrollment
* At time of enrollment, \</=10 anterior chamber cells/HPF and vitrous haze\</= grade 2.

Exclusion Criteria:

* known allergy or contraindication to fluocinolone acetonide, systemic corticosteroids, or the immunosuppressive agents to be administered
* history of retinal detachment, retinoschisis in the area of implantation, or media opacity precluding evaluation of the retina and vitreous
* presence or history of uncontrolled IOP while on steroid therapy resulting in loss of vision, or IOP \>25 mm Hg requiring at least 2 types of antiglaucoma medication to be reduced to \<25 mm Hg
* history of NIPU only or iritis only with no vitritis, macular edema, vitreous cells, or vitreous haze
* infectious etiology, vitreous hemorrhage, or a toxoplasma scar in the study eye
* ocular surgery and/or trauma on the study eye within 3 months prior to enrollment, or trabeculoplasty or yttrium aluminum garnet laser within 1 month prior to study enrollment
* monocularity
* AIDS
* pregnancy/lactation
* potential for noncompliance
* or participation in other clinical studies within 1 month of enrollment.

Answer: D